Cargando…

Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?

BCG vaccine is usually considered to be safe though rarely serious complications have also been reported, often incriminating contamination of the seed strain with pathogenic Mycobacterium tuberculosis. In such circumstances, it becomes prudent to rule out the contamination of the vaccine seed. M. b...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Sarman, Kumar, Manoj, Singh, Pragati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324913/
https://www.ncbi.nlm.nih.gov/pubmed/25694828
http://dx.doi.org/10.1155/2015/957519
_version_ 1782356748793806848
author Singh, Sarman
Kumar, Manoj
Singh, Pragati
author_facet Singh, Sarman
Kumar, Manoj
Singh, Pragati
author_sort Singh, Sarman
collection PubMed
description BCG vaccine is usually considered to be safe though rarely serious complications have also been reported, often incriminating contamination of the seed strain with pathogenic Mycobacterium tuberculosis. In such circumstances, it becomes prudent to rule out the contamination of the vaccine seed. M. bovis BCG can be confirmed by the absence of nitrate reductase, negative niacin test, and resistance to pyrazinamide and cycloserine. Recently in India, some stocks were found to be niacin positive which led to a national controversy and closer of a vaccine production plant. This prompted us to write this review and the comparative biochemical and genotypic studies were carried out on the these contentious vaccine stocks at the Indian vaccine plant and other seeds and it was found that some BCG vaccine strains and even some strains of M. bovis with eugenic-growth characteristics mainly old laboratory strains may give a positive niacin reaction. Most probably, the repeated subcultures lead to undefined changes at the genetic level in these seed strains. These changing biological characteristics envisage reevaluation of biochemical characters of existing BCG vaccine seeds and framing of newer guidelines for manufacturing, production, safety, and effectiveness of BCG vaccine.
format Online
Article
Text
id pubmed-4324913
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-43249132015-02-18 Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker? Singh, Sarman Kumar, Manoj Singh, Pragati Tuberc Res Treat Review Article BCG vaccine is usually considered to be safe though rarely serious complications have also been reported, often incriminating contamination of the seed strain with pathogenic Mycobacterium tuberculosis. In such circumstances, it becomes prudent to rule out the contamination of the vaccine seed. M. bovis BCG can be confirmed by the absence of nitrate reductase, negative niacin test, and resistance to pyrazinamide and cycloserine. Recently in India, some stocks were found to be niacin positive which led to a national controversy and closer of a vaccine production plant. This prompted us to write this review and the comparative biochemical and genotypic studies were carried out on the these contentious vaccine stocks at the Indian vaccine plant and other seeds and it was found that some BCG vaccine strains and even some strains of M. bovis with eugenic-growth characteristics mainly old laboratory strains may give a positive niacin reaction. Most probably, the repeated subcultures lead to undefined changes at the genetic level in these seed strains. These changing biological characteristics envisage reevaluation of biochemical characters of existing BCG vaccine seeds and framing of newer guidelines for manufacturing, production, safety, and effectiveness of BCG vaccine. Hindawi Publishing Corporation 2015 2015-01-28 /pmc/articles/PMC4324913/ /pubmed/25694828 http://dx.doi.org/10.1155/2015/957519 Text en Copyright © 2015 Sarman Singh et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Singh, Sarman
Kumar, Manoj
Singh, Pragati
Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?
title Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?
title_full Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?
title_fullStr Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?
title_full_unstemmed Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?
title_short Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?
title_sort evolution of m. bovis bcg vaccine: is niacin production still a valid biomarker?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324913/
https://www.ncbi.nlm.nih.gov/pubmed/25694828
http://dx.doi.org/10.1155/2015/957519
work_keys_str_mv AT singhsarman evolutionofmbovisbcgvaccineisniacinproductionstillavalidbiomarker
AT kumarmanoj evolutionofmbovisbcgvaccineisniacinproductionstillavalidbiomarker
AT singhpragati evolutionofmbovisbcgvaccineisniacinproductionstillavalidbiomarker